Core Insights - Seer, Inc. will present new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference, showcasing advancements in scalable deep cellular proteomics using the Proteograph™ Product Suite [1][2] - The seminar will feature a groundbreaking study on a co-delivery therapeutic platform targeting cancer vulnerabilities, utilizing both siRNA and mRNA therapeutics [1][5] - The study aims to simultaneously inactivate tumorigenic drivers and activate lost tumor suppressors, establishing a new strategy for treating a wide range of cancers [1][5] Company Overview - Seer, Inc. is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite, which integrates engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis [10] - The Proteograph workflow is designed to be efficient and user-friendly, allowing for decentralized implementation in various laboratory settings [10] Event Details - The seminar titled "Transforming Cancer Research with Deep Cellular Proteomics" will be presented by Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School on February 25, 2025 [4] - Additional presentations at the conference will highlight the role of the Proteograph Product Suite in various proteomic studies, including tissue biology and cardiometabolic dysfunction [2][6]

Core Viewpoint - Seer, Inc. is set to report its financial results for Q4 and full year 2024 on February 27, 2025, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - Seer, Inc. is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software for deep, unbiased proteomic analysis [3] - The workflow is designed to be efficient and user-friendly, allowing integration into various laboratory settings [3] - The Proteograph Product Suite is intended for research use only and is not meant for diagnostic procedures [3]

Company Participation - Seer, Inc. will participate in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA [1] - The management is scheduled to present and engage in a Q&A session on January 15 at 3:00 p.m. Pacific Time [2] Product Overview - Seer is a life sciences company focused on developing transformative products for proteomics [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis [3] - The Proteograph workflow is designed to be efficient and user-friendly, allowing integration into various laboratory settings [3]

SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international. BROOMFIELD, CO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has partnered with DevvStream, Inc., an emerging leader in carbon credit investi ...

DevvStream Enters Biogas Market via Partnership with Methane Renewable Energy LeaderDecember 12, 2024 7:30 AM EST | Source: DevvStream Corp.Carbon Management Program by SEER and DevvStream will be centered around biogas capture and carbon sequestration through biocarbon, or biochar, productionCompanies plan to leverage over 150 existing SEER-affiliate biogas installations across North America with numerous multinational utility companies, food processors, brewers, and agriculture firms as well ...

REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Seer grew 2,440% during this period. Seer’s President and CFO, David Horn, credits increased adoption ...

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MAFireside chat on Monday, November 11th at 11:30 a.m. Eastern TimeCanaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, No ...

Seer, Inc. (NASDAQ:SEER) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - CEO and Chair David Horn - CFO and President Conference Call Participants Jaden Rismay - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Seer, Inc. Third Quarter 2024 Earnings Conference Call [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.35, delivering a surprise of 2.78%.Over the last four quarters, the company has surpassed con ...

Table of Contents Copies to: Title of each class Trading Symbol(s) Name of Exchange on which registered Common Stock, par value $0.00001 SEER Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra ...